Eli Lilly and Company – Consensus Indicates Potential 12.8% Upside

Broker Ratings

Eli Lilly and Company found using ticker (LLY) have now 19 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 255 and 170 with a mean TP of 212.36. Now with the previous closing price of 188.2 this indicates there is a potential upside of 12.8%. There is a 50 day moving average of 185.08 while the 200 day moving average is 176.2. The market cap for the company is $184,998m. Company Website: http://www.lilly.com

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext; Avidity Biosciences; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits
You might also enjoy reading  Eli Lilly and Company - Consensus Indicates Potential 3.7% Upside

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index